-- Company communicates progress on numerous indicators of
economic, environmental and social performance
INDIANAPOLIS, Dec. 3, 2012 /PRNewswire/ -- Eli Lilly
and Company (NYSE: LLY) has released its 2011/2012 Corporate
Responsibility Update
(www.lilly.com/Documents/Lilly_2011_2012_CRupdate.pdf). This report
highlights progress and initiatives since Lilly's 2010/2011 full
Corporate Responsibility Report. The update, as well as last year's
full report, is available on Lilly's website at
www.lilly.com.
"Increasingly, we are integrating the concept of 'shared value'
into the way we operate," said John C.
Lechleiter, Ph.D., Lilly chairman, president and chief
executive officer. "Using our business expertise to help address
pressing social needs opens up new opportunities for us to provide
solutions to health challenges the world over. We believe this
approach will help to create enduring value for society and for
Lilly. By making individual patients better, we help those
patients—as well as their communities and broader societies—to
thrive."
Lilly, a leader in advocating for greater transparency by the
biopharmaceutical industry, provides a comprehensive report of the
company's progress on numerous corporate responsibility goals and
efforts. The report includes updates on longstanding programs, as
well as data for 2011.
Included in the report are highlights indicating that Lilly:
- gave more than $590 million in
charitable contributions in 2011 (including cash, products, and
other in-kind donations), including through the company's patient
assistance programs, which helped more than 250,000 people;
- unveiled The Lilly Global Health Innovation Campaign, which
encompassses two of Lilly's signature corporate responsibility
programs – The Lilly NCD Partnership and The Lilly MDR-TB
Partnership – aimed at improving health for people in need in
developing countires;
- received a perfect score of 100 on the Human Rights Campaign's
"Best Places to Work: Corporate Equality Index" in 2011;
- selected 200 employees to volunteer two weeks each, on company
time, in countries where people lack resources or access to quality
health care;
- reduced serious injury and lost-time injury rates each by 50
percent (from 2007 baseline);
- decreased water intake by more than 25 percent and waste to
landfill by 40 percent compared to 2007;
- improved energy efficiency by more than 15 percent, compared to
2007, and reduced corresponding greenhouse gas emissions by more
than 15 percent.
The Lilly 2011/12 Corporate Responsibility Update also serves as
the company's annual Communication on Progress to the United
Nations Global Compact (UNGC). As a signatory of the UNGC, Lilly
shares its progress annually on 10 principles universally accepted
related to human rights, labor, the environment and
anti-corruption.
The report details the company's progress in areas such as:
- conducting business ethically and transparently,
including the safe, uninterrupted supply of medicines, ethical
product promotion, patient privacy, public disclosure of clinical
trial results and financial payments to health care professionals;
- enhancing access to medicines and efforts to improve
health for people in need, including through patient assistance
programs and product donations;
- developing innovative medicines and maintaining the
highest standards in research and development, including the use
and care of animals in research, bioethics, patient safety and
education, and diversity in clinical trials;
- supporting strong workplace practices that encompass
diversity and inclusion; employee health, safety and wellness;
recruiting, hiring and development; and efforts to help employees
maintain work-life balance;
- engaging with patients and communities to achieve better
health outcomes, including community-based programs that support
patients, improving health disparities, and employee volunteering
and giving programs;
- fostering environmental sustainability and reducing the
company's environmental footprint through initiatives related to
energy efficiency, greenhouse gases emissions, water intake and
waste to landfill.
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation is developing a
growing portfolio of pharmaceutical products by applying the latest
research from its own worldwide laboratories and from
collaborations with eminent scientific organizations. Headquartered
in Indianapolis, Ind., Lilly
provides answers – through medicines and information – for some of
the world's most urgent medical needs. Additional information about
Lilly is available at www.lilly.com. CR-LLY
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )